CorMedix Inc
CRMD16.560USD
+2.950+21.68%
Handelsschluss 06/23, 16:00（ET）Kurse um 15 Minuten verzögert
1.12BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über CorMedix Inc Unternehmen
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Unternehmensinformationen
BörsenkürzelCRMD
Name des UnternehmensCorMedix Inc
IPO-datumMar 25, 2010
Gegründet am2006
CEOMr. Joseph Todisco
Anzahl der mitarbeiter64
WertpapierartOrdinary Share
GeschäftsjahresendeMar 25
Addresse300 Connell Drive
StadtBERKELEY HEIGHTS
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl07922
Telefon19085179500
Websitehttps://cormedix.com/
BörsenkürzelCRMD
IPO-datumMar 25, 2010
Gegründet am2006
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Umsatzaufteilung
FY2024
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
43.47M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
13.86%
Investment Advisor/Hedge Fund
13.60%
Hedge Fund
5.69%
Research Firm
1.60%
Sovereign Wealth Fund
1.39%
Individual Investor
1.19%
Pension Fund
0.45%
Bank and Trust
0.30%
Venture Capital
0.06%
Other
61.88%
Institutionelle Beteiligung
Aktualisiert: Mon, Feb 24
Aktualisiert: Mon, Feb 24
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
262
29.51M
43.73%
+3.54M
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
2022Q4
191
11.93M
28.90%
-1.83M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
4.20M
6.44%
+868.26K
+26.06%
Dec 31, 2024
The Vanguard Group, Inc.
3.38M
5.18%
+309.51K
+10.09%
Dec 31, 2024
Elliott Management Corporation
2.87M
4.4%
+1.32M
+85.14%
Dec 31, 2024
State Street Global Advisors (US)
1.45M
2.23%
+227.39K
+18.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.39M
2.14%
+108.36K
+8.44%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
940.59K
1.44%
+940.59K
--
Dec 31, 2024
UBS Financial Services, Inc.
379.87K
0.58%
+340.35K
+861.30%
Dec 31, 2024
Morgan Stanley & Co. LLC
283.12K
0.43%
+50.06K
+21.48%
Dec 31, 2024
Northern Trust Investments, Inc.
510.89K
0.78%
+100.11K
+24.37%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Active Factor Small Cap ETF
0.17%
iShares Micro-Cap ETF
0.13%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.49%
First Trust Active Factor Small Cap ETF
Anteil0.17%
iShares Micro-Cap ETF
Anteil0.13%
Vanguard US Momentum Factor ETF
Anteil0.1%
Invesco Nasdaq Biotechnology ETF
Anteil0.08%
iShares Biotechnology ETF
Anteil0.07%
ProShares Ultra Nasdaq Biotechnology
Anteil0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
